Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma

NCT06630806 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT06630806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06630806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human, Open-label, Phase 1 Study to Evaluate the Safety, Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of Subcutaneous SAR446523, an Anti-GPRC5D ADCC-enhanced Monoclonal Antibody, in Participants With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Sanofi
Phase
Phase 1
Overall status
Recruiting
Start date
October 30, 2024
Completion date
May 16, 2031
Enrollment
87 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

plasma cell myeloma refractory